(Total Views: 316)
Posted On: 07/31/2019 6:58:27 AM
Post# of 88
***Folks...Here is an article that shows why Dr. Gregory-Evans On-going Medical Research Project in Macular Degeneration using Protokinetix's
...molecule..AAGP..Will do so well..
https://www.nature.com/articles/s41433-018-0061-z
ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC
Marietta, Ohio, July 9, 2019
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQB
KTX) has reached the mid-point of 3rdstage of testing in retinal cell replacement therapy at the University of British Columbia. Functionality testing on experimental models three months post-transplant show encouraging results. We anticipate results from six-month post-transplant to be available within the next 4-5 weeks. The study includes two experimental models over a longer period of time to test whether the AAGP® treated cells continue to develop and mature into retinal cells to potentially restore vision in humans. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
“We are pleased that our functional studies to date are looking positive and very significant.” – Dr. Kevin Gregory-Evans
...molecule..AAGP..Will do so well..
https://www.nature.com/articles/s41433-018-0061-z
ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC
Marietta, Ohio, July 9, 2019
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
(OTCQB KTX) has reached the mid-point of 3rdstage of testing in retinal cell replacement therapy at the University of British Columbia. Functionality testing on experimental models three months post-transplant show encouraging results. We anticipate results from six-month post-transplant to be available within the next 4-5 weeks. The study includes two experimental models over a longer period of time to test whether the AAGP® treated cells continue to develop and mature into retinal cells to potentially restore vision in humans. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia. “We are pleased that our functional studies to date are looking positive and very significant.” – Dr. Kevin Gregory-Evans
(0)
(0)
